Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Role of TG2 and TGF-β1 in the Pathogenesis of Human Breast Cancer.

Transforming Growth Factor-β1 and -Β2 in Gastric Precancer and Cancer and Roles in Tumor-Cell Interactions with Peripheral Blood Mononuclear Cells in Vitro

TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway

TGF-β1 Gene Silencing Can Enhances the Sensitivity of Breast Cancer to Cisplatin Partially by Restraining the Occurrence of EMT.

Transglutaminase 2 in breast cancer metastasis and drug resistance

The Role of TGFBI in Mesothelioma and Breast Cancer: Association with Tumor Suppression

TGFBI Protein High Expression Predicts Poor Prognosis in Colorectal Cancer Patients.

Expression of TGF-β1 and the mechanism of invasiveness and metastasis induced by TGF-β1 in breast cancer

Role of TGF-β1 and Its Receptors in Breast Carcinogenesis:Evaluation of Gene Expression Patterns and Clinical Implications

Transcriptomics studies reveal functions of Transglutaminase 2 in breast cancer cells using membrane permeable and impermeable inhibitors

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

TGF-β1 Induces HMGA1 Expression in Human Breast Cancer Cells: Implications of the Involvement of HMGA1 in TGF-β Signaling

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Biological Effects of Connective Tissue Growth Factor Transfection on Human Breast Cancer Cells

The expression of CD44v6, TGF -β1 and TGF -βR Ⅱ protein in breast neoplasm and its relationship with parameters of clinicopathological characteristics

Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis

Expression and Clinical Significance of Transforming Growth Factor Beta Receptor Type Ⅱ in Cervical Carcinoma

Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancer

The molecular mechanism of transforming growth factor-β1-induced transmembrane protein participating in the development of breast cancer

Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer

The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis